---
title: Antimetabolites - Chemotherapy
type: content
phase: 1
status: complete
priority: high
tags: [chemotherapy, antimetabolites, 5-FU, methotrexate, cytarabine, gemcitabine, antifolates, pyrimidine-analogs, purine-analogs]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antimetabolites - Chemotherapy

## Introduction

Antimetabolites are structural analogs of normal metabolites required for DNA/RNA synthesis. They interfere with nucleotide synthesis or incorporation, leading to cell death. These drugs are cell cycle S-phase specific and most effective against rapidly dividing cells.

## Mechanism of Action

**General Principle**:
- **Structural analogs** of normal metabolites (folate, purines, pyrimidines)
- **Compete** with normal metabolites
- **Inhibit enzymes** in nucleotide synthesis
- **Incorporate** into DNA/RNA → dysfunction
- **S-phase specific** (DNA synthesis phase)

**Classes**:
1. **Antifolates** (inhibit folate metabolism)
2. **Pyrimidine analogs** (interfere with pyrimidine synthesis/function)
3. **Purine analogs** (interfere with purine synthesis/function)

---

## Antifolates

### Methotrexate (MTX)

**Mechanism**:
- **Inhibits dihydrofolate reductase (DHFR)**
- DHFR converts dihydrofolate → tetrahydrofolate (THF)
- THF required for **thymidylate synthesis** (DNA) and **purine synthesis**
- **Blocks DNA/RNA synthesis**

**Pharmacokinetics**:
- Oral, IV, IM, IT (intrathecal)
- **Poor oral absorption** at high doses (saturable)
- **Renal excretion** (70-90% unchanged)
- **Third-space accumulation** (ascites, pleural effusions) → prolonged half-life, toxicity

**Clinical Uses**:
1. **Acute lymphoblastic leukemia (ALL)** - high-dose with leucovorin rescue
2. **Lymphomas** (non-Hodgkin's)
3. **Breast cancer**
4. **Head and neck cancer**
5. **Osteosarcoma** - high-dose
6. **Choriocarcinoma** (highly curable)
7. **CNS prophylaxis** - intrathecal
8. **Autoimmune diseases**: Rheumatoid arthritis, psoriasis (low-dose)
9. **Ectopic pregnancy** (medical management)

**Dosing**:
- **Low-dose**: 7.5-25 mg/week PO (RA, psoriasis)
- **Moderate**: 50-100 mg/m2 IV
- **High-dose**: 1-12 g/m2 IV (with **leucovorin rescue**)

**Leucovorin Rescue** (Folinic Acid):
- **Bypasses DHFR** (reduced folate)
- **Rescues normal cells** from MTX toxicity
- **Start 24 hours** after high-dose MTX
- **Continue until MTX level <0.05 μM**
- **Essential for high-dose MTX** (prevents fatal toxicity)

**Adverse Effects**:

**Myelosuppression**:
- Dose-limiting (without rescue)
- Nadir: 7-14 days

**Mucositis** (Oral, GI):
- **Common** (30-40% high-dose)
- Painful mouth sores, diarrhea
- **Prevention**: Good oral care, leucovorin

**Hepatotoxicity**:
- **Acute**: ↑LFTs (reversible)
- **Chronic** (low-dose): Hepatic fibrosis, cirrhosis
  - Risk: Cumulative dose >1.5 g, alcohol, obesity, diabetes
  - **Monitor LFTs**

**Nephrotoxicity** (High-Dose):
- **MTX precipitation** in renal tubules (acidic urine)
- **Prevention**:
  - **Aggressive hydration** (3 L/day)
  - **Urinary alkalinization** (sodium bicarbonate - keep pH >7)
  - **Monitor MTX levels**

**Pulmonary Toxicity**:
- **Pneumonitis, fibrosis** (rare, unpredictable)
- Can occur at any dose
- Presents with dyspnea, cough, fever

**Neurotoxicity** (Intrathecal):
- **Acute**: Aseptic meningitis
- **Chronic**: Leukoencephalopathy (cognitive decline)

**Teratogenicity**:
- **Highly teratogenic** (neural tube defects)
- **Contraindicated in pregnancy**

**Drug Interactions**:
- **NSAIDs**: ↓MTX excretion → toxicity
- **Penicillins, proton pump inhibitors**: ↑MTX levels
- **Trimethoprim**: Additive antifolate effect

**Monitoring** (High-Dose):
- **MTX levels** (24, 48, 72 hours)
- **Cr, BUN** (renal function)
- **Urine pH** (keep >7)
- **Continue leucovorin** until MTX <0.05 μM

**Antidote**: **Glucarpidase** (Voraxaze)
- Rapidly ↓MTX levels (cleaves MTX)
- **Reserved for** severe MTX toxicity with renal failure

**Clinical Pearls**:
- **Leucovorin rescue essential** for high-dose MTX
- **Hydration + alkalinization** prevent nephrotoxicity
- **NSAIDs contraindicated** with high-dose MTX
- **Monitor MTX levels** (high-dose)
- **Weekly dosing** for RA/psoriasis (daily dosing is fatal error)

### Pemetrexed (Alimta)

**Mechanism**: Multi-targeted antifolate (inhibits DHFR, thymidylate synthase, others)

**Clinical Uses**:
1. **Mesothelioma** (with cisplatin)
2. **Non-small cell lung cancer** (non-squamous)

**Supplementation Required**:
- **Folic acid** 400-1000 mcg daily (start 7 days before)
- **Vitamin B12** 1000 mcg IM every 9 weeks
- **Reduces toxicity** (rash, myelosuppression, diarrhea)

**Adverse Effects**:
- Myelosuppression
- Rash (↓with folic acid/B12)
- Fatigue

**Clinical Pearl**: **Always supplement folic acid/B12** (reduces toxicity)

### Pralatrexate

**Mechanism**: Antifolate (DHFR inhibitor)

**Clinical Uses**: **Peripheral T-cell lymphoma**

**Supplementation**: Folic acid + vitamin B12 (like pemetrexed)

---

## Pyrimidine Analogs

### 5-Fluorouracil (5-FU)

**Mechanism**:
- **Inhibits thymidylate synthase (TS)**
  - 5-FU → 5-FdUMP → binds TS with methylene-THF
  - **Blocks dTMP synthesis** → ↓DNA synthesis (thymineless death)
- **Incorporation into RNA** → dysfunction

**Pharmacokinetics**:
- **IV only** (extensive first-pass)
- Short half-life (10-20 minutes)
- **Continuous infusion** often used (S-phase specific)

**Clinical Uses**:
1. **Colorectal cancer** (FOLFOX, FOLFIRI regimens)
2. **Gastric, esophageal, pancreatic cancer**
3. **Breast cancer**
4. **Head and neck cancer**
5. **Anal cancer** (with radiation)

**Leucovorin Enhancement**:
- **Leucovorin** (folinic acid) ↑5-FU efficacy
- Stabilizes 5-FU-TS-methylene-THF complex
- **Commonly combined** (FOLFOX = 5-FU + Leucovorin + Oxaliplatin)

**Adverse Effects**:

**Diarrhea** (Dose-Limiting):
- Can be severe, life-threatening
- **Monitor closely**, hold therapy if severe

**Myelosuppression**:
- Dose-limiting (bolus dosing)

**Hand-Foot Syndrome** (Palmar-Plantar Erythrodysesthesia):
- **Painful erythema**, swelling of palms/soles
- More common with **continuous infusion**, **capecitabine**
- **Treatment**: Dose reduction, emollients, cooling

**Mucositis**:
- Painful mouth sores

**Cardiotoxicity** (Rare, 1-5%):
- **Coronary vasospasm** → angina, MI
- More common with continuous infusion
- **Stop if chest pain**

**Neurotoxicity** (Rare):
- Cerebellar ataxia
- Risk: DPD deficiency (see below)

**DPD Deficiency** (Dihydropyrimidine Dehydrogenase):
- **Enzyme metabolizes 5-FU**
- **Deficiency** (3-5% population) → severe, life-threatening toxicity
- **Consider testing** before treatment

**Clinical Pearls**:
- **Continuous infusion** preferred (S-phase specific)
- **Combined with leucovorin** (↑efficacy)
- **Watch for diarrhea** (dose-limiting)
- **DPD deficiency** → severe toxicity (consider testing)

### Capecitabine (Xeloda)

**Relationship**: **Oral prodrug of 5-FU**
- Converted to 5-FU by thymidine phosphorylase (high in tumors)
- **"Tumor-activated"**

**Advantages**:
- **Oral** (convenient, outpatient)
- **Tumor-selective** activation

**Clinical Uses**: Similar to 5-FU (colorectal, breast, gastric)

**Adverse Effects**: Similar to 5-FU
- **Hand-foot syndrome** (more common than IV 5-FU)
- Diarrhea, myelosuppression

**Clinical Pearl**: **Oral alternative to IV 5-FU** (better hand-foot syndrome)

### Cytarabine (Ara-C)

**Mechanism**:
- **Pyrimidine analog** (cytidine)
- **Incorporates into DNA** → chain termination
- **Inhibits DNA polymerase**

**Pharmacokinetics**:
- IV, SC, IT (intrathecal)
- **Rapidly metabolized** by cytidine deaminase → inactive
- Short half-life (requires continuous infusion or frequent dosing)

**Clinical Uses**:
1. **Acute myeloid leukemia (AML)** - **backbone of therapy** (7+3 regimen)
2. **Acute lymphoblastic leukemia (ALL)**
3. **Lymphomas** (high-grade)
4. **CNS prophylaxis** - intrathecal

**Dosing**:
- **Standard**: 100-200 mg/m2/day × 7 days (7+3 with anthracycline)
- **High-dose**: 3 g/m2 q12h (CNS penetration, refractory AML)

**Adverse Effects**:

**Myelosuppression** (Severe, Universal):
- **Pancytopenia** (expected with AML treatment)

**Mucositis, GI Toxicity**:
- Common (especially high-dose)

**Cerebellar Toxicity** (High-Dose, 10-25%):
- **Ataxia, dysarthria, nystagmus**
- **Can be irreversible**
- Risk factors: Age >50, renal impairment, cumulative dose
- **Limit dose in elderly**

**Hepatotoxicity**:
- ↑LFTs, cholestasis

**Conjunctivitis**:
- Common (high-dose)
- **Prevention**: **Steroid eye drops** (dexamethasone qid during therapy)

**Cytarabine Syndrome**:
- Fever, myalgias, bone pain, rash (6-12 hours post-dose)
- Responsive to steroids

**Clinical Pearls**:
- **Backbone of AML therapy** (7+3 regimen)
- **High-dose for CNS penetration** (CNS leukemia, high-risk)
- **Steroid eye drops** prevent conjunctivitis (high-dose)
- **Watch cerebellar toxicity** (high-dose, elderly)

### Gemcitabine (Gemzar)

**Mechanism**:
- **Pyrimidine analog** (deoxycytidine)
- **Incorporates into DNA** → chain termination
- **Inhibits ribonucleotide reductase** → ↓dNTP pools

**Pharmacokinetics**:
- IV infusion
- Metabolized by cytidine deaminase

**Clinical Uses**:
1. **Pancreatic cancer** (first-line)
2. **Non-small cell lung cancer**
3. **Bladder cancer**
4. **Ovarian cancer**
5. **Breast cancer**

**Adverse Effects**:

**Myelosuppression**:
- **Dose-limiting**
- Especially thrombocytopenia

**Flu-like Syndrome**:
- Fever, myalgias (common, first dose)

**Pulmonary Toxicity**:
- Dyspnea (rare)

**Hepatotoxicity, Nephrotoxicity**:
- ↑LFTs, proteinuria

**Hemolytic Uremic Syndrome (HUS)** (Rare, <1%):
- Microangiopathic hemolytic anemia, thrombocytopenia, renal failure
- **Stop drug immediately**

**Clinical Pearl**: **Standard for pancreatic cancer** (well-tolerated)

### Azacitidine, Decitabine

**Mechanism**:
- **Hypomethylating agents**
- **Inhibit DNA methyltransferase** → DNA hypomethylation
- **Reactivate tumor suppressor genes**

**Clinical Uses**:
1. **Myelodysplastic syndromes (MDS)**
2. **Acute myeloid leukemia** (elderly, unfit for intensive chemo)

**Adverse Effects**:
- Myelosuppression, nausea, injection site reactions

**Clinical Pearl**: **Standard for MDS** (improve survival vs. supportive care)

---

## Purine Analogs

### 6-Mercaptopurine (6-MP)

**Mechanism**:
- **Purine analog**
- **Inhibits purine synthesis** (multiple enzymes)
- **Incorporates into DNA/RNA**

**Pharmacokinetics**:
- Oral
- Metabolized by **thiopurine methyltransferase (TPMT)** and **xanthine oxidase**

**Clinical Uses**:
1. **Acute lymphoblastic leukemia (ALL)** - maintenance therapy
2. **Inflammatory bowel disease** (Crohn's, UC - immunosuppression)

**TPMT Deficiency**:
- **Enzyme metabolizes 6-MP**
- **Deficiency** (1 in 300) → severe myelosuppression
- **Test TPMT activity** before starting (genotype or phenotype)
- **Reduce dose** if deficient

**Drug Interactions**:
- **Allopurinol**: Inhibits xanthine oxidase → ↑6-MP levels
  - **Reduce 6-MP dose 75%** if on allopurinol
  - **Use febuxostat** instead (doesn't affect 6-MP)

**Adverse Effects**:
- Myelosuppression
- Hepatotoxicity, cholestasis
- Nausea
- Immunosuppression (infections)

**Clinical Pearls**:
- **Test TPMT** before starting (genetic polymorphism)
- **Reduce dose with allopurinol** (75% reduction)
- **Maintenance therapy for ALL** (long-term)

### 6-Thioguanine (6-TG)

**Similar to 6-MP**

**Clinical Uses**: AML, ALL

**Advantage**: **No interaction with allopurinol** (different metabolism)

### Fludarabine

**Mechanism**: Purine analog (adenine)
- Inhibits DNA polymerase, ribonucleotide reductase
- Incorporates into DNA

**Clinical Uses**:
1. **Chronic lymphocytic leukemia (CLL)** - previously first-line (now targeted therapy preferred)
2. **Non-Hodgkin's lymphoma**
3. **Conditioning regimen** (stem cell transplant - reduced intensity)

**Adverse Effects**:
- **Severe immunosuppression** (T-cell depletion)
  - **Opportunistic infections** (PCP, CMV, fungal)
  - **PCP prophylaxis** required (TMP-SMX)
- Myelosuppression
- Neurotoxicity (high-dose)
- Autoimmune hemolytic anemia

**Clinical Pearl**: **Potent immunosuppressant** - PCP prophylaxis essential

### Cladribine (2-CdA)

**Clinical Uses**:
1. **Hairy cell leukemia** - highly effective (single course curative)

**Adverse Effects**: Severe immunosuppression, myelosuppression

### Pentostatin

**Mechanism**: **Adenosine deaminase inhibitor**

**Clinical Uses**: Hairy cell leukemia

**Adverse Effects**: Severe immunosuppression, renal toxicity

---

## Clinical Pearls

1. **Antimetabolites are S-phase specific** - most effective rapidly dividing cells
2. **Methotrexate**: DHFR inhibitor, leucovorin rescue (high-dose), hydration + alkalinization (nephrotoxicity), NO NSAIDs
3. **5-FU**: Thymidylate synthase inhibitor, combine with leucovorin (↑efficacy), continuous infusion preferred, DPD deficiency → severe toxicity
4. **Capecitabine**: Oral 5-FU prodrug, hand-foot syndrome common
5. **Cytarabine**: Backbone AML therapy (7+3), high-dose for CNS, cerebellar toxicity (elderly), steroid eye drops
6. **Gemcitabine**: Pancreatic cancer standard, well-tolerated
7. **6-MP**: Test TPMT (deficiency → severe toxicity), reduce dose 75% with allopurinol
8. **Pemetrexed**: Supplement folic acid + B12 (reduces toxicity)
9. **Leucovorin**: Rescues from MTX (folinic acid), enhances 5-FU efficacy
10. **Fludarabine**: Severe immunosuppression - PCP prophylaxis required

---

## Key Takeaways

1. **Mechanism**: Analogs of normal metabolites, inhibit nucleotide synthesis, S-phase specific
2. **Antifolates**: Methotrexate (DHFR inhibitor), pemetrexed (multi-targeted)
3. **Pyrimidine analogs**: 5-FU (TS inhibitor), cytarabine (AML backbone), gemcitabine (pancreatic cancer)
4. **Purine analogs**: 6-MP (TPMT testing), fludarabine (CLL, severe immunosuppression)
5. **Leucovorin**: Rescues from MTX toxicity, enhances 5-FU efficacy
6. **MTX toxicity**: Myelosuppression, mucositis, nephrotoxicity (hydration + alkalinization), avoid NSAIDs
7. **5-FU toxicity**: Diarrhea, hand-foot syndrome, DPD deficiency risk
8. **Cytarabine toxicity**: Myelosuppression (universal), cerebellar (high-dose), conjunctivitis (steroid eye drops)
9. **Drug interactions**: MTX + NSAIDs, 6-MP + allopurinol, pemetrexed (need folate/B12)
10. **Rescue/prevention**: Leucovorin (MTX), folic acid/B12 (pemetrexed), TMP-SMX (fludarabine PCP prophylaxis)

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition
4. NCCN Clinical Practice Guidelines in Oncology
5. Relling MV, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011.
